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1. Introduction 
Internal radiation dosimetry has a fundamental and growing role in planning nuclear 
medicine therapies with radionuclides. 
The principle of nuclear medicine therapy is to destroy pathologic tissues through the 
irradiation with the ionizing radiation emitted by properly chosen radionuclides, while 
preserving other organs and tissues from unnecessary exposure to the same radiation. 
In order to realize this result, proper pharmaceuticals are chosen with a biodistribution 
targeted on target tissues, and labelled with a suitably chosen radionuclide. The choice of the 
best radionuclide is carried on with the aim of maximizing radiation energy deposition in the 
target tissue during the desired treatment time. Beta-emitters are the best choice in most cases, 
because beta radiation has a mean range in tissue from few millimetres to few centimetres. 
Also used are alpha- and Auger-emitters, for millimetre and sub-millimetre ranges. 
The absorbed dose to the target tissues as well as to other organs and tissues depends from 
the biokinetics of the radiopharmaceutical and from the physical decay scheme of the 
radionuclide employed. While the physical properties of each nuclide are well known from 
experimental data, the biodistribution of the radiopharmaceutical within the patient's body 
depends on the dynamic biologic pathway that in turns is governed by the role of the 
molecule, by the characteristics of the patient, by the type and stage of the disease, and by 
the route of administration.  
The distribution of radioactivity within the human body must be sampled several times 
post-administration, by means of planar or tomographic (SPECT or PET) imaging 
techniques. Tomographic techniques are rapidly substituting planar whole body imaging, 
since, thanks also to the accurate attenuation correction and image co-registration brought 
by a simultaneous CT scan, they reach a spatial resolution and an accuracy in activity 
quantification unprecedented. 
After a general introduction on dosimetric quantities and their relationships, we focus on 
the dosimetric anthropomorphic models. We introduce also 3D techniques based on voxel 
dose factors, convolution of dose point-kernels and direct Monte Carlo computation, 
focusing on the contribution of Monte Carlo simulation to the development of new and 
more accurate dosimetric and microdosimetric models for internal dosimetry. 
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We describe the application of such dosimetric approaches in the main nuclear medicine 
therapies such as the 131I therapy of thyroid diseases, the therapy of neuroendocrine 
tumours (NET) with somatostatin analogues labelled with beta- or Auger-emitters, and the 
palliation of painful bone metastases, focusing on dose-efficacy relationships and on the 
limiting of side effects to other potentially critical organs. 
2. Definitions 
If we consider a radioactive volume containing, at the time t, N radioactive nuclei, we know 
that the activity A(t), representing the number of decays per second, is proportional to N 
through the decay constant λ: 
 ( ) dNA t = = λN
dt
−                     (1) 
Equation 1 can be integrated, leading to the exponential decay law for the number of radio-
atoms present at the time t in a radioactive sample: 
 λt0N = N e−                                    (2) 
The decay constant λ is related to the decay time τ and to the half-life T1/2 by the 
relationships: 
 1/2
ln2
ln2T = = τλ                                 (3) 
The SI unit of activity is the Becquerel (Bq), defined as one disintegration per second: 
 11 1Bq = dis s−⋅ , (4) 
while the old unit of activity was the Curie (Ci): 
 101 3.7 10Ci = Bq×  (5) 
The radiation absorbed dose, commonly intended as dose, is defined as the average energy 
imparted by the radiation per unit mass of the irradiated volume: 
 
dE
D =
dm
                                (6) 
In the SI system, the dose is expressed in joules per kilogram or Gray (Gy); the older unit, no 
longer employed but often encountered in aged texts, was the Rad (1 erg/g). The conversion 
is such that 1 Gy = 100 Rad. 
In internal dosimetry, the dose to an organ or tissue accumulating a radiopharmaceutical 
can be evaluated following the MIRD approach (Snyder et al., 1975).  
The dose imparted to a target volume k from a single source volume h, can be calculated as: 
 ( ) ( )k h h k hD r r = A S r r← ←#                    (7) 
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where hA
#  is the cumulated activity in the source organ and S is the average dose absorbed 
by the target per unit cumulated activity in the source. The cumulated activity in h is 
defined as the total number of disintegrations in that organ, i.e. the integral of the activity A 
over the time: 
 ( )
0
h hA = A t dt
∞
∫#  ,                       (8) 
The definition of the S factor appearing in Equation 7 is: 
 ( )
( )i i k h
i
k h
k
Δφ r r
S r r =
m
←
←
∑
      (9) 
where Δi is the average energy emitted per transition as i-th radiation, φi is the “absorbed 
fraction”, i.e. the fraction of the energy emitted in the source volume rh which was absorbed 
in the target volume rk, and mk is the mass of the target. 
In general, if several organs accumulate the radiopharmaceutical, the overall dose to the 
target volume (organ or tissue) k is obtained by summing up all the contributions coming 
from the various regions h: 
 ( ) ( ) /k h i i k h h
h i
D r = A ΔΦ r r m←∑ ∑#                  (10) 
Another usually employed quantity is the residence time, defined as the ratio between the 
cumulated activity in h and the administered activity A0: 
 
0
h
h
Aτ =
A
#
 (11) 
Even if the residence time has the physical dimensions of a time and it is often indicated 
with the same Greek letter, it must not be confused with the decay time of a radionuclide. In 
fact, while the decay time is the time necessary to reduce by 1/e = 0.37 the activity of an 
isolated sample, the residence time is the length of time an activity A0 would have to reside 
in the volume to give that cumulated activity.  
3. Radiobiological models of the radiation effects 
The estimation of the effect of the radiation absorbed dose in biological tissues can not 
neglect biological models accounting for the ability of tissues and cells to repair in some 
degree the radiation-induced injury. (Cremonesi, 2011; Strigari, 2011) 
The radiation damage can vary due to the different tissue properties (the ͆five Rs͇ of 
radiobiology: repair, repopulation, reoxigenation, redistribution and intrinsic radiosensitivity) in 
tumours and in healthy tissues, and due to the difference in possible irradiation regimes 
(type and energy of the radiation, dose rate, repetition or fractionation of treatments). 
In nuclear medicine therapies with radiopharmaceuticals, the radiation dose is often 
imparted by beta or Auger electrons, even if the role of alpha emitters as therapeutic agents 
is increasing again. 
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Thus, the dose and the dose rate in the single treatment are governed by the biokinetics of 
the radiopharmaceutical and by the administered activity and route of administration.  
The biological effect of such irradiation in tumours and in healthy tissues will depend firstly 
on the repair ability of the sub-lethal damage with related repair time Trep, which is due to 
the mechanisms that counteract all the natural damages to the DNA. This is the fastest 
mechanism influencing the response to irradiation, since its effects are detectable in external 
irradiations already after 30 minutes. 
The cell life cycle is divided in four consecutive steps: G1, S, G2 and M. The two gaps of 
apparent inactivity, G1 and G2, divide the two active phases, the DNA synthesis S and the 
mitosis M. Radiobiology studies demonstrated that the highest cell radiosensitivity belongs 
to G2 and M phases. After an irradiation,  the survival fraction will be higher for cells in the 
G1 or S phases; thus a redistribution of population is initiated, with a synchronization of cell 
life cycles. 
This effect could, in principle, play a certain role in external irradiations repeated at the 
times of higher sensitivity, but no clear evidence of efficacy has been demonstrated yet. 
Cells surviving to an exposure to radiations will continue to proliferate; such a repopulation 
has a detrimental effect on therapeutic results. On the other hand, tumour cell death leads to 
tumour tissue shrinkage and, consequently, can improve the reoxigenation of the residual 
hypoxic cells. Since hypoxic cells are more radio-resistant than the oxygenated ones, 
repeated cycles of irradiation are useful to improve therapeutic outcomes. 
As a consequence of these mechanisms, the effect of a radiation therapy depends not only 
on the radiation absorbed dose, but also on the dose rate and on the fractionation regime. 
The most widely applied radiobiological model describing cell survival after irradiations is 
the linear-quadratic model, in which the effect E, in logarithmic relation with the surviving 
fraction SF, is a function of the dose D and the dose squared: 
 ( )log 2E = SF = D + ǃDα−  (12) 
The linear component accounts for the lethal cell damage given by a single radiation 
producing, for example, double-strand breaks of the DNA helix, while the quadratic 
component accounts for the lethal damage obtained by summing up the effects of two 
consecutive ionizing radiations. It should be noticed that the parameter α has dimensions of 
Gy-1, while β of Gy-2. The dose in correspondence of which the linear contribution L equals 
the quadratic one Q (see Fig. 1), is given by D= α/β (Gy). This value expresses the intrinsic 
radiosensitivity of the tissue, and external as well as internal radiation therapies exploit the 
higher radiosensitivity of cancer cells with respect to normal tissue cells. 
When the radiation dose is imparted in a time T comparable or even longer than the repair 
time of the sub-lethal damage, Trep, Eq. 12 must be corrected in order to account for the 
competition between radiation-induced damage and cell repair rate: 
 ( ) ( )log 2E = SF = D + g T ǃDα−  (13) 
where g(T) is a properly chosen function of the irradiation time. When T>>Trep, as in the case 
of targeted radionuclide therapies, it was demonstrated that a good approximation is: 
 
rep
rep eff
T
g =
T + T
 (14) 
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where Teff is the effective half-life of the radionuclide in the target tissue. 
 
 
Fig. 1. Cell surviving fraction as a function of the radiation dose, following the linear-
quadratic (LQ) model. Linear (L) and quadratic (Q) part of the equation are represented, too. 
In the proposed example, α/β = 25 Gy. 
The Biologically Effective Dose (BED) is defined in a way such that the effect E is linearly 
related to BED through the parameter ͉: 
 E = BEDα  (15) 
From Eq. 13, BED is related to the cell surviving fraction and to the dose with the 
relationships: 
 ( ) ( ) 21 log ǃBED = SF = D + g T Dα α−    (16) 
For radionuclide therapies, Eq. 14 holds for the correction factor g, resulting, for a single 
irradiation imparting a radiation dose D: 
 2
rep
rep eff
Tǃ
BED = D + D
T + Tα  (17) 
In the case of repeated irradiations, each one imparting a dose Di, the total BED can be 
calculated as: 
 2
rep
i i
rep eff
Tǃ
BED = D + D
T + Tα∑ ∑  (18) 
In the next Sections, we will see how BED is related to the impairment of kidneys after 
repeated cycles of peptide radio-receptor therapies (PRRT) with somatostatin analogues 
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labelled with beta-emitting radioisotopes. In such evaluations, it is usually assumed ͉/͊ = 
2.4 Gy and for Trep a value of 2.8 hours. 
4. Time sampling and determination of the cumulated activity 
In Section 2, the main equations of internal dosimetry were introduced, and the role played 
by the cumulated activity, i.e. the total number of disintegrations in the considered target, 
was taken in evidence. 
In general, the biokinetics of a radiopharmaceutical within the human body will be 
influenced by the type of the carrier molecule and its physiologic and pathologic pathway, 
by the route of administration and by the preparation and clinical state of the patient. 
Clinical studies and trials give information about the average residence times of groups of 
patients, but, in order to plan the single treatment, only an accurate individualized 
dosimetry can be usefully employed. 
In order to calculate the cumulated activity, the activity up-taken in each organ or region of 
interest must be properly sampled after administration. In principle, more measurements 
allow a more accurate fit of the A=A(t) curve, and, consequently, a better estimation of the 
total number of disintegrations. 
However, we must remember that each measurement is carried out through planar 
scintigraphic or emission computed tomography (ECT) techniques, which are time 
consuming for both patient and hospital personnel. 
Even in the case of non-imaging techniques, such as thyroid uptake measurements with a 
scintillation probe, the patient must come back to the nuclear medicine department for each 
measurement. 
Hence the need to optimize dosimetric protocols in order to the number and timing of the 
acquisitions. The optimal choice will depend on the expected biokinetics of the 
radiopharmaceutical in the organs of interest, which can be assumed from previous clinical 
studies. 
The simplest model applies when the uptake phase, i.e. the phase in which the 
radiopharmaceutical is accumulating in the organ and its radioactivity rises with time, is 
short enough to be considered instantaneous. Consequently, immediately after 
administration, the washout phase begins.  
If, in the simplest assumption, the radiopharmaceutical is washed out with a mono-
exponential rate, the variation of N with time follows a law analogous to Eq. 1: 
 eff
dN
= λ N
dt
 (19) 
where the effective decay constant eff bioλ = λ + λ  is given by the sum of the physical decay 
constant introduced in Eq. 1 and the biological decay constant, characteristic of the 
biological wash-out of the radiopharmaceutical from the organ. In analogy with Eq. 3, the 
effective decay time τeff and the effective half-life Teff can be defined as: 
 
ln2
ln2eff eff
eff
T = = τλ  (20) 
and the cumulated activity will be: 
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0
λeff
eff
t A
A = A e dt = λ
∞ −∫#  (21) 
In more complex cases, the uptake phase can require a certain amount of time and, 
consequently, the assumption of instantaneous uptake must be released and the uptake 
phase can be usually described by an exponential growth. Furthermore, the washout phase 
can be not accurately described by a simple mono-exponential decay. For example, a bi-
exponential curve can fit better to a biokinetical behaviour composed by a first phase of 
rapid clearance in which the biologic half-life is much smaller than the physical half-life, 
followed by a slower retention phase in which, on the contrary, it is the physical half-life 
that governs the overall effective half-life. 
In Figure 2, an example of near-instantaneous uptake, followed by a washout phase 
described by a bi-exponential decay, is shown. The renal uptake of a diagnostic dose of 111In-
DTPA-Octreotide, a somatostatin analogue used for the diagnosis of neuroendocrine 
tumours, was imaged at 1, 6, 24 and 48 hours post-injection. 
 
 
Fig. 2. Uptake curves for kidneys in four patients after 111In-DTPA-Octreotide intravenous 
administration. 
In Figure 3 we present three examples of 131I uptake curves for hyperthyroid patients (pt. 1 
and 2 affected by toxic nodular goitre, TNG, and the third by Basedow disease), acquired by 
means of a scintillation probe at six times after oral administration of a diagnostic activity of 
1.8 MBq.  
In these cases, the uptake phase is expected to last up to one day, followed by a decay phase 
with a characteristic half-life of 100-200 hours, deriving from both physical (eight days) and 
biological decay. 
Thanks to the simplicity and rapidity of thyroid uptake measurements with a gamma probe, 
it is possible to sample properly in time these patients. Usually, two measurements during 
the first day, 3 and 6 hours after oral administration, properly characterize the uptake phase. 
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Measurements can proceed at 24, 48, 72 (or 96, or 120) and 168 hours, in order to detect the 
maximum uptake and the decay phase. 
Points can be then fitted with the function: 
 ( ) ( )in outin
out in
λλmaxλ U ttU t = e eλ λ
−− −−  (22) 
where the uptake and washout constants λin and λout depend upon the rapidity of the 
increase and decrease in uptake, respectively. 
Even if the maximum uptake is expected, on average, around 24 hours, this is not a rigid 
rule, of course. Patient 3, for example, reached the maximum uptake already at the sixth 
hour, and the fit of patient 1 data show its maximum earlier than 24 hours; cases of late 
maxima are observed, too. 
In order to evaluate properly the effective half-time of the washout phase, measurements 
should extend at least up to 120 hours, better up to 168 hours. In fact, since each point is 
affected by statistical fluctuations and by minor biases due to the practical procedure, 
repeated measurements help in reducing errors in fit.  
As an example, in Figure 3 we represent, together with the fits of the whole data series (solid 
lines), the fits obtained by considering only the first four points, i.e. 3, 6, 24 and 48 hours 
(dashed lines). 
It is apparent from figure the underestimation of the decay time for the first patient, and, on 
the contrary, the overestimation for the second one. 
Such outcome is confirmed numerically by the results reported in Table 1, where the 
effective half-time of the washout, Teff, is calculated from the decay constants obtained from 
the complete fit and from the 3-48 hours data. Results from incomplete data give a 24% 
shorter half-time for the first patient, while for the second one an overestimation as high as 
91% comes from a dosimetric protocol limited to 48 hours. 
 
 
Fig. 3. 131I uptake curves for the three patients. Solid curves represent the analytical fits of 
complete data series with Eq. 22, dashed lines represent fits of 3-48 hours data. 
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Pt. no. Umax λin λout λout(48h) Teff Teff(48h) error 
1 (TNG) 23184 0.184 7.41E-3 9.72E-3 93 71 -24% 
2 (TNG) 16755 0.142 5.62E-3 2.95E-3 123 235 +91% 
3 (Bas.) 35920 0.740 4.42E-3 4.66E-3 157 148 -6% 
Table 1. Fit parameters for the complete data series, and for the first four points. Relative 
error in Teff determination are reported. 
5. Anthropomorphic models for internal dosimetry 
In the past decades, several schematic anthropomorphic models were proposed in order to 
standardize and simplify dose calculation both in medical applications of radionuclides and 
in internal contamination evaluations for radiological protection purposes. 
Among these, a common approach to internal dosimetry is based on standardized phantoms 
and S factors pre-calculated for couples of Source-Target organs and for various 
radionuclides (Snyder et al., 1975). 
Organ S factors were calculated through Monte Carlo simulations and are currently 
available in a tabular form. As a consequence, once calculated the cumulated activity in the 
source organ with the methods described in the previous Section, the dose to the target 
organ is calculated with Equation 7, using the proper S factor accounting for the 
radionuclide emission and for the geometry of the source-target couple. 
An advantage of this method is the simplicity of measurements and the standardization of 
the dosimetric procedure, allowing easier comparisons between results. However, the 
simplified organ models, described by fixed geometrical shapes and volumes, do not 
account properly for the anatomy of the single patient. Furthermore, each organ is treated as 
a whole, neglecting inhomogeneity in the uptake within each organ or tissue. 
In real cases, the shape and size of an organ can be varied by a disease, and pathologic 
tissues, which are the target of the treatment, are not present in standard models of healthy 
humans.  
A sphere model is often employed in order to represent small target tissues such as tumours 
or pathologic lymph-nodes. Recently, we developed a model to calculate the absorbed 
fractions in ellipsoidal shapes uptaking beta-gamma emitting radionuclides (Amato et al. 
2009, 2011). 
Considering a radionuclide which emits mono-energetic and beta electrons, and gamma 
photons, the average dose to the target volume is given by: 
 ( ) ( ) ( )ǃ e Ǆ e,i e,i e,i Ǆ,i Ǆ,i Ǆ,i
i
dn EA
D = D + D + D = Eφ E dE + n E φ + n E φ
m dE
⎡ ⎤⎢ ⎥⎣ ⎦∑∫
#
, (23) 
where ne and nγ are the mono-energetic electron and gamma photon emission probabilities, 
respectively, of energies Ee and Eγ , φe and φγ are the electron and photon absorbed fractions. 
These absorbed fractions can be derived from the equation: 
 ( )
1
01
s
ǒφ ǒ = + ǒ
−⎛ ⎞⎜ ⎟⎜ ⎟⎝ ⎠
 (24) 
where ǒ is the “generalized radius”, defined as: 
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 3
Vǒ=
S
 (25) 
where V and S are the volume and surface of the ellipsoid. The parameters ǒ0 and s in 
Equation 24 depend on the nature (electron or photon) and energy of the radiation, and can 
be derived from proper parametric functions described in (Amato et al. 2009, 2011). 
In Figure 4, the absorbed fraction as a function of the generalized radius is reported for 
photons and electrons uniformly emitted in ellipsoids of various shapes. These data are 
calculated by means of a Monte Carlo simulation in Geant4. 
 
 
Fig. 4. Electron and photon absorbed fraction in ellipsoidal volumes, as a function of the 
generalized radius (Amato et al. 2009, 2011). 
6. Three-dimensional dosimetry 
Traditional approaches to internal dosimetry employ anatomic models to obtain mean 
organ doses. With the diffusion of SPECT-CT and PET-CT tomographs,  dosimetric methods 
which can utilize non-uniform activity distributions to derive dose distributions within 
organs become increasingly important.  
This result can be obtained either with dose point-kernel convolution methods, or by means 
of a direct Monte Carlo simulation, or exploiting the voxel S factor approach. 
The voxel S factor approach, introduced in (Bolch et al., 1999), has been used more widely 
than dose point-kernel and direct Monte Carlo computation approaches, due to its 
recognized simplicity. 
Following this approach, the average dose to the k-th voxel can be calculated as: 
 k h k hD = A S ←⋅∑ #  (26) 
where hA
#  is the cumulated activity in the generic h-th voxel and k hS ←  is the voxel S factor, 
defined as: 
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( )i
k h i
k
φ k h
S = Δ
m
←
←⋅∑  (27) 
where iΔ  is the mean energy emitted as radiation i per decay, iφ  is the absorbed fraction in 
k of the radiation i emitted in h, and mk is the mass of the k-th voxel. 
In (Bolch et al., 1999), voxel S factors were tabulated for five radionuclides and two cubic 
voxel sizes. Recently, Dieudonnè et al. (2010) presented a generalization of this approach to 
variable voxel sizes, which allows to obtain S factors for a generic voxel size for nine 
radionuclides by means of a resampling method. 
The dose point-kernel gives the dose per decay event at a given distance from a point source 
located inside an infinite and homogeneous absorbing medium. Dose point-kernels for 
electrons and photons were calculated by means of Monte Carlo simulations, and are 
available either in tabular form or as analytical functions obtained fitting the simulative data 
(Mainegra-Hing et al., 2005) (Maigne et al., 2011).  
By convolving the dose point-kernels evaluated for the actual radionuclide spectrum in the 
three-dimensional distribution obtained from the volume distribution of cumulated activity, 
obtained from SPECT-CT or PET-CT images, one can retrieve the volume distribution of the 
absorbed dose. In order to speed up calculations, fast Fourier or fast Hartley transformations 
can be employed. 
Finally, the Monte Carlo approach is the most demanding in terms of computational power, 
but it is the only one which can account accurately for tissue inhomogeneity. Known the 
three-dimensional map of tissue density and composition from CT scan and the volume 
distribution of the cumulated activity through SPECT or PET emission tomography, it is 
possible to generate a fixed number of decay events statistically distributed in space 
according to emission tomography data within the patient’s body reconstructed from CT 
and track all the emitted secondaries in order to calculate the geometrical distribution of 
energy deposition, i.e. the three-dimensional map of absorbed dose, and finally to rescale 
the results to the actual values of cumulated activity (Furhang et al., 1997). 
7. 
131
I therapy of hyperthyroidism 
Hyperthyroidism is a consequence of an excess in free-thyroid hormone action on the 
tissues. The most frequent causes of hyperthyroidism are: Graves' Disease (GD), Toxic 
Adenoma (TA) or Toxic Multinodular Goiter (TMG). In any cases, hyperthyroidism can be 
caused by sub-acute thyroiditis or silent thyroiditis. 
The treatment of GD, TA and TMG can be symptomatic with anti-thyroid drugs (often used 
as first line therapy) or definitive: radioiodine therapy (RaIT) or surgery (total or near-total 
thyroidectomy). 
RaIT is a well established method for the treatment of hyperthyroidism; aim of the RaIT is to 
achieve an euthyroid or hypothyroid (such as in the Graves patients) status. 
Presently, the optimal 131I activity to be administered is still matter of debate.  
Many authors evaluated the effectiveness of different dosimetric methodologies. The results 
were variable and often controversial, in order to the frequency of recurrence and 
hypothyroidism (Regalbuto et al., 2009) (Giovannella, 2000). 
In order to determine the 131I activity to be administered for the treatment of 
hyperthyroidism, fixed activity and adjusted activity approaches are currently employed. In 
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both cases it is necessary, if possible, to suspend anti-thyroid drugs treatment 4-6 days 
before RaIT or thyroid scintigraphy. 
The 131I “fixed”activity for RaIT is usually about 555 MBq. In such case, the thyroid 
scintigraphy with or without radioiodine thyroid uptake (RTU) curve can be not necessary. 
In the adjusted activity approach, a dosimetric procedure is employed which requires two 
diagnostic steps: a) thyroid ultrasonography to calculate the volume of the gland, or the hot 
thyroid nodule(s), assuming for them an ellipsoidal shape; b) thyroid scintigraphy and RTU 
measurements after 131I tracer activity administration (1.8 MBq).  
The dosimetric method most frequently employed was proposed by the MIRD commission 
(Snyder et al., 1975). In this approach, RTU measurements are usually conducted between 3 
and 120 hours after administration. Multiple RTU measurements allow to calculate the 
effective half-life of the radioiodine into the hot nodules or in the whole gland (Figure 3).  
In TMG and TA patients, the effective volume of the hot nodule(s) was calculated taking 
into account the presence of involving area(s) (whole nodule volume - involving area 
volume). 
The radiation doses to be imparted to the gland (GD) or to the nodule(s) (TA and TMG) are 
up to 200 and 300 Gy, respectively. 
In GD with ophtalmopathy, the radiation dose to be imparted must be adjusted, up to a 
maximum value of 250 Gy. In these patients, it is useful to administer anti-inflammatory 
drugs for a time duration ranging from 4 to 12 weeks after RaIT. 
In all patients, the choice of the therapeutic dose will be determined also in function of: sex 
and age, type of hyperthyroidism (overt or sub-clinical) and its temporal duration, 
concomitant Hashimoto thyroiditis, anti-thyroid drugs therapy and its temporal duration. 
Basing on the above considerations, the activity to be administered can be calculated as: 
 
1/2
5.829
max eff
Dm
A =
U T
 (28) 
where A is the activity to be administered in MBq in order to impart a dose D in cGy to the 
target (nodule or gland) of mass m in g, Umax is the maximum per cent radioiodine uptake 
(usually measured at 24 hours) and T1/2eff is the effective half-time in hours. 
Recently, Amato et al. (2011) proposed an improved calculation method for the activity to be 
administered during the radioiodine treatment of hyperthyroidism. In this approach, a 
Monte Carlo simulation had been employed to derive the radiation dose in nodules or in the 
whole gland within an anthropomorphic phantom, taking into account the ellipsoidal shape 
of the target volumes. 
As a result, the activity to be administered can be calculated with the formula: 
 ( )1/2
32.31 1
0.2625 5.1819max eff
ǒ+Dm
A =
U T ǒ ǒ+⋅  (29) 
where we recall the definition of generalized radius, ǒ=3V/S, stated in Equation 12, and 
here expressed in cm. The volume and the surface of the ellipsoidal target (nodule or 
thyroid lobe) can be calculated from the semiaxes measured through ultrasonography as: 
 
4
3
V = Ǒabc ,      ( ) ( ) ( )
1/
4Ǒ
3
pp p p
ab + bc + ac
S =
⎛ ⎞⎜ ⎟⎜ ⎟⎝ ⎠
 (30) 
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8. 
131
I therapy of differentiated thyroid carcinoma 
Differentiated thyroid cancer (DTC) is the most common cancer of the endocrine system. 
The first line therapy is represented by total or near-total thyroidectomy (with dissect of the 
sixth lymph nodes level and, if necessary, of the lateral-cervical lymph nodes of the same 
side respect to primary lesion). 
After Total or near-Total Thyroidectomy (nTT) it is useful to ablate the thyroid remnant 
with 131-radioiodine therapy (RaIT). In fact, several Authors, such as Mazzaferri et al. (1997) 
demonstrated that the prognosis quod vitam and the survival curve of the DTC-patients 
significantly improve if RaIT follows TT or NTT. 
In addition, the ablation of thyroid remnant (TRA) allows a better management of the 
follow-up of these patients. 
In fact, in the patients treated with TT or NTT and TRA, the Thyroglobulin (hTg) serum 
levels should be undetectable. Thus, any enhancement of hTg serum (both under L-T4 
suppressive therapy or after exogenous TSH stimulation -rhTSH-) can be considered as a 
relapse of disease. 
RaIT can be carried out in hypothyroidism state (TSH>=30) or after rhTSH stimulation. 
Post dose whole body scan and static images of the head, neck and thorax acquired 4-8 days 
after RIT allow to identify the thyroid remnant and metastases (loco-regional and/or distant). 
For the RaIT of TRA, fixed activities are employed more frequently: 1110, 2220 or 3700 MBq. 
In the patients treated after rhTSH stimulation it is necessary to employ a medium-to-high 
activity of radioiodine (2220 and 3700 MBq, respectively), because in this condition the 
effective half-life of radioiodine in the thyroid remnant is shorter than in the state of 
hypothyroidism. 
However, the TRA activity can be adjusted through a dosimetric approach (Lassmann, 
2010), which requires a pre-therapeutic scintigraphy with 131I or 124I PET. The dose to the 
thyroid remnant can be calculated using 131I post-therapy whole body scan, too. 
Both methods show advantages and disadvantages. The main disadvantage of the pre-
therapeutic scintigraphic method is correlated to the stunning or mass change effects that 
could be determined by a diagnostic activity of 131I. 
On the other hand, the main disadvantage of the post-therapeutic scintigraphic method is 
correlated to technical difficulties such as the limitations deriving from the gamma-camera 
dead time. 
The clinical evidence demonstrated that the dosimetry adjusted activities do not differ 
significantly from the fixed values. Thus, in the clinical practice, the dosimetric approach is 
not employed frequently. However, the dosimetric approach is useful for the treatment of 
loco-regional and/or distant metastases. 
Dosimetry is particularly useful in patients with lung and/or bone metastases, where 
standard activities can lead to a radiation dose imparted to the lesions lower than the 
necessary. In such cases, it is necessary to acquire some whole scans starting from 6-7 hours 
after radio-iodine therapy. (Eschmann et al., 2002) (Sgouros et al., 2004). 
9. Usefulness of radiopharmaceuticals for the palliation of painful bone 
metastases 
The development of bone metastases is commonly related to a serious reduction in quality 
of patient life because of pain occurrence and side effects of analgesics intake, especially 
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opiates (Silberstein, 2001). Therapeutic options for pain palliation include systemic therapy 
with cytotoxic agents, diphosphonate therapy, external beam radiotherapy and radionuclide 
therapy. Diphosphonate therapy has become a possible option for the treatment of patients 
affected by bone metastases since a new generation of diphosphonate has been developed; 
using zoledronic acid, indeed, the clinical benefits of diphosphonate (skeletal complications 
reduction and analgesic effects on bone pain), previously limited to patients with bone 
metastases from breast cancer or lesions due to multiple myeloma, have been extended to 
patients with bone metastases secondary to a broad range of solid tumors (Berenson, 2005). 
However, diphosphonates achieve only a modest analgesic effect and are associated with 
some non-renal adverse effects (Hillner, 2003; Lewington, 1996). External beam radiotherapy 
is the therapy of choice in cases of a single site of pain. However, when multiple painful 
metastases have been developed, local field radiotherapy is less effective and hemibody 
radiotherapy is associated with a significant morbidity (Lewington, 1996). Furthermore, 
external beam radiotherapy is often not suitable for repeated treatments. On the other hand, 
bone-seeking beta-emitting radiopharmaceuticals represent an effective tool for pain 
palliation in patients with multifocal bone disease, and make it possible to perform multiple 
administrations (Lam, 2004; Daformou, 2001; Englaro, 1992; Maini, 2003). Pain arises from 
both umoral and mechanical effects, including bone invasion, micro-fractures, increased 
intramedullary pressure and periosteal stretching (Lewington, 2005). Unlike opiates, which 
affect the entire nervous system, radionuclides exert their action mainly on cells at the 
peripheral nerve endings, where inflammatory, immune and malignant cells accumulate 
and release chemicals that modulate pain at the site of malignant invasion (Krishnamurthy, 
2000). Furthermore, early response gene induction and a psychological-placebo component 
could account for the pain alleviation effect (Lewington, 1996; Leondi, 2004; Roche, 1994; 
Hellmann, 1994).  
The goals of therapy are to alleviate pain, improve quality of life and mobility, reduce 
dependence on narcotic and non-narcotic analgesics, and improve performance status and 
possibly survival (Minutoli, 2006; Hindorf, 2011). 
Bone tumours can be divided into osteolytic and sclerotic tumours. Sclerotic tumours are 
more suitable for targeted radionuclide therapy because of higher uptake of the 
radiopharmaceutical within the lesions. The majority of bone metastases from prostate 
cancer are sclerotic whilst metastases of breast cancer generally are mixed 
osteolytic/sclerotic. Also patients with bone metastases from tumours other than prostate 
and breast cancer and increased 99mTc-MDP uptake on bone scan can benefit from targeted 
radionuclide therapy (Leondi, 2004; Minutoli, 2006).  
Two radiopharmaceuticals for the treatment of bone tumours are currently approved by the 
European Medicines Agency (EMEA): 153Sm-EDTMP (Quadramet®) and 89Sr-Cl2 (Metastron®). 
Other radiopharmaceuticals are at different stages of research, or are approved in some 
European Countries. These include 186Re-HEDP, 117mSn-DTPA and 223Ra-Cl2 (Alpharadin
®). 
The use of 32P is now considered to be obsolete. 
Strontium-89 was suggested for the treatment of bone tumours during the 1940s. It is 
naturally taken up in bone and is a pure β- emitter with a long half-life (50.53 days). 
Pharmacokinetic and dosimetry studies have been based on imaging of 85Sr-Cl (Blake, 1986, 
1987, 1998; Breen, 1992), although imaging based on bremsstrahlung photons from 89Sr has 
also been performed (ICRP, 1997). Tumour dosimetry is generally performed under the 
assumption that the activity uptake is five times higher than for normal bone. Strontium 
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leaves the blood quickly after an intravenous injection. The kidneys are the main route of 
excretion, but the gut has been seen in scintillation camera images and IRCP report assumes 
4:1 ratio for urinary to faecal excretion. 
Tin-117m labelled DTPA is investigated for the treatment of bone pain from metastases. Tin-
117m can be imaged via the 156 keV gamma photons and the main energy deposition is 
performed by the corresponding conversion electrons. The conclusion from a phase I/II 
clinical study was that 117mSn-DTPA is an effective and safe radiopharmaceutical for the 
treatment of bone metastases (Krishnamurthy, 1997; Srivastava, 1998). 
153Sm-EDTMP is a therapeutic agent consisting of radioactive samarium and a 
tetraphosphonate chelator, ethylenediaminetetramethylenephosphonic acid (EDTMP). It is 
formulated as a sterile, non-pyrogenic, clear, colorless to light amber isotonic solution of 
samarium-153 lexidronam for intravenous administration (37 MBq/kg body weight) (Bodei, 
2008). Onset of pain relief comes within one week, lasting from four weeks up to four 
months. The highest absorbed dose is received by bone marrow and bone surfaces. Imaging 
is commonly performed three hours after injection to verify the activity uptake. All activity 
not taken up in bone is excreted via urine and no further activity is excreted 24 hours after 
the injection. Dosimetry can therefore be performed from one scintillation camera imaging 
acquired 24h after injection or from one single probe measurement. The activity uptake in 
bone has been reported  to increase with an increase in number of bone tumors (Farhangi, 
1992; Brenner, 2001). 
Renium-186 is a beta minus emitter with a maximum beta energy of 1.07 MeV. The physical 
half-life is 89 hours. The radiopharmaceutical is taken up in bone via the phosphor complex 
HEDP (hydroxyethylidene diphosphonate). Quantitative imaging for pharmacokinetics and 
dosimetry is possible via the emission of 137 keV photons with a 9.47% probability. 
Excretion is predominantly through the kidneys.  
Radium-223-chloride is taken up in bone by natural affinity. It decays in six steps into stable 
207Pb. The injected activity has been reported as 46-250 kBq per kg of whole body weight 
(Nilsson, 2005, 2007). A clinical phase II study showed an improved survival without severe 
toxicity after four weekly injections of 50 kBq per kg of whole body weight compared to 
placebo injections (Nilsson, 2007). The photon emissions at 81.1 keV and 83.8 keV show the 
highest emission probabilities and offer the best opportunity to perform quantitative 
imaging during the treatment, which enables pharmacokinetic and dosimetric studies to be 
performed. The main route of excretion is via faeces (Hindorf, 2008). 
Contraindications for radionuclide therapy are a life expectancy shorter than four weeks, 
severe renal insufficiency, and low blood counts due to a compromised bone marrow 
function. The absorbed dose to the tumour is the factor that determines the effectiveness of 
the therapy while the absorbed dose to the bone marrow correlates to the toxic effects 
received. The bone marrow is the dose limiting organ when bone-seeking 
radiopharmaceuticals are used (Lewington, 1993). Radionuclide therapy for pain palliation 
from bone metastases is currently performed based on a pre-set injected activity. The 
patients will, therefore, receive a range of absorbed doses due to individual differences in 
the pharmacokinetics. Voxel based, patient specific dosimetry automatically takes into 
account individual differences in pharmacokinetics and macroscopic anatomy. Furthermore, 
Monte Carlo simulations also take into account different cross sectional interaction data for 
all materials present in the body, which is, therefore, more accurate than convolution with a 
dose point kernel as this is based on an assumption of infinite, uniform medium. 
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Radionuclide therapy as a palliative treatment of bone pain is efficient, although improved 
dosimetry methods could help to improve the treatment further.  
10. Peptide radio-receptor therapy of neuroendocrine tumours 
Neuroendocrine tumours (NETs) derive from the neuroendocrine cell system, which is 
widely distributed in the body, and are a heterogeneous group of neoplasms characterized 
by embryological, biological and histo-pathological differences. The most frequent sites of 
NETs are the gastrointestinal tract (70%) and the bronco-pulmonary system (25%), followed 
by the skin, the adrenal glands, the thyroid and the genital tract.  
Present classification is based on tumour biology and patho-histological features (cellular 
grading, primary tumour size and site, cell proliferation markers, local or vascular 
invasivity and the production of biologically active substances), which are crucial to guide 
the diagnostic work-up and therapeutic planning.  
The great majority are benign (well-differentiated neuroendocrine tumours) or slow-
growing  neoplasms with a low grade of malignancy. Poorly differentiated endocrine 
carcinomas have a high grade of malignancy and a poor prognosis. Furthermore, a few 
moderately differentiated tumours with cellular and structural types intermediate between 
well and poorly differentiated NETs have also been found. 
A typical feature of differentiated NETs is the expression of several specific receptors on the 
cell membrane and in particular of somatostatin receptors (SSTR) which can be visualized 
by somatostatin receptor imaging with radiolabelled somatostatin analogues (111In-
OCTREOSCAN, 68Ga-DOTANOC). These radiopharmaceuticals bind with high affinity to 
subtypes 2, 5 and 3 of SSTR and provide an approximation of somatostatin receptor density, 
having a positive predictive value of the therapeutic efficacy of the somatostatin analogues.  
Peptide receptor radionuclide therapy (PRRT) is an effective tool for the treatment of 
tumours with a high somatostatin receptor density. 
This approach is based on the administration of a therapeutic activity of radiolabelled 
somatostatin analogues. Radiopharmaceutical with various radionuclides and peptides are 
currently available.  
High activities of 111In-DTPA-octreotide (OCTREOSCAN®), the same radiopharmaceutical 
used for imaging, have been used in pilot trials and in some experiences (Herberg, 2009, 
2011). Besides the gamma radiation of 111In used for scintigraphic scans (Ǆ photons of 172 
and 245 keV),  its therapeutic effect is due to the emission of Auger and conversion electrons 
with a medium-to-short tissue penetration range (0.02-10 and 200-500 μm, respectively). Its 
potential effect depends on the preservation of mechanism of octreotide-receptor complex 
internalization (through endocytosis) and its translocation to the nuclear compartment, 
where short path-length Auger or conversion electrons are able to reach the target (DNA). In 
clinical trials, 111In-DTPA-octreotide showed a low rate of tumour regression: the most 
accredited explanation is that 111In electrons fail to reach the DNA helix, possibly due to the 
lack of nuclear receptors that were never definitely demonstrated (Kwekkeboom, 2005). 
The radiopeptides for PRRT that have been studied most extensively are 90Y-DOTATOC and 
177Lu-DOTATATE. These beta-emitting radiolabelled peptides are preferred for their 
advantageous physical properties. 
90Y (Emax = 2.28 MeV, Rmax = 11 mm, <E> = 0.935 MeV; half-life 2.67 days) has a pure beta 
emission with long range particles that, besides the direct action, lead to irradiation also of 
no-receptor expressing tumour-cell (cross-fire effect). For these reasons 90Y-peptides are 
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preferred especially for the treatment of larger and inhomogeneous  lesions. In figure 5, the 
comparison between electron paths within small and large inhomogeneous lesions is 
represented through a Monte Carlo simulation in Geant4, in which radiations emitted from 
177Lu and 90Y are compared. 
177Lu has a longer half-life (6.7 days) and lower energy beta-emission (Emax = 0.497 MeV; 
Rmax = 2 mm) that allows to concentrate all the energy inside smaller tumours; moreover the 
gamma-emission of 177Lu (113 keV and 208 keV) is suitable for scintigraphy and dosimetry 
during PRRT.  
 
 
Fig. 5. Comparison between the high-energy electron tracks (red) of 90Y and the ones of the 
lower-energy electrons from 177Lu. Photons originating from gamma ray emission or 
bremsstrahlung are represented in green. 
Concerning peptides, several new somatostatin analogues have been introduced for 
therapeutic and diagnostic purposes, including the agonists DOTA-(1-NaI3)octreotide 
(DOTANOC) and DOTA-(BzThi3)octreotide (DOTABOC).  
D =2 mm
Dext =2 cm 
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Y-90
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These compounds have a broader somatostatin receptor affinity profile than DOTATATE 
and DOTATOC because of a higher affinity for sst3 and sst5 in addition to their high affinity 
for sst2. This could increase the number of tumours that could benefit from PRRT in the 
future.  
Recently, peptides targeting all the sst receptors (pansomatostatins) have shown high 
affinity of 90Y-DOTA-cyclo(D-diaminobutyric acid-Arg–Phe–Phe-D-Trp–Lys–Thr–Phe) (90Y-
KE88) for all 5 sst receptors and, in future, they could improve the therapeutic potential of 
sst-targeted PRRT. 
To date, the therapy administration protocols rely essentially on empirical criteria with 
injection of standard activities, as derived from escalation studies or clinical experience, at 
variable time intervals (6-12 weeks).  
For therapy optimization and prevention of toxicity, dosimetry represent a precious guide, 
providing evaluation of biodistribution, pharmacokinetics, radiation doses  and biological 
effective doses to healthy organs and tumours.  
The gamma-emission of 111In and 177Lu-peptide enable imaging, dosimetry and therapy with 
the same compound.  In the case of 90Y-peptide, for the lack of gamma emission, the same 
analogue radiolabeled with 111In or positron emitters as 86Y or 68Ga can be used as surrogates 
for dosimetric imaging. Some recent studies have been published for 90Y-peptide dosimetry 
with bremsstrahlung images through SPECT-TC systems, or exploiting the rare positron 
decay of 90Y imaged by new generation PET-CT scanners.  
A dosimetric protocol consists in the acquisition of multiple planar whole-body (WB) scan to 
obtain biokinetics data over the time (at least 4-5 acquisitions at different times), 
complementary SPECT imaging to evaluate intra-organ activity distribution (especially at 
the level of the kidneys and in tumour lesion), WB transmission imaging for attenuation 
correction, blood and urine samples. Anatomical imaging (CT or ultrasonographic) provide 
important parameters for organ mass evaluation (Cremonesi, 2011).   
Dose calculation can be performed in the framework of the MIRD formalism, in order to 
obtain average dose estimates at the organ level assuming standard phantom models, with 
possible organ mass adjustments according to patient data. Voxel dosimetry method or 
direct Monte Carlo simulation can provide more reliable dose estimates.   
Pharmacokinetic studies have shown fast blood clearance and urinary elimination. The 
higher uptake has been noticed in the spleen, kidneys and liver and no uptake is visible in 
the bone marrow in normal conditions. Pharmacokinetic data of different radiopeptides are 
similar but not identical: as the peptide influences biokinetics, for the single patient the data 
need to be assessed specifically with regard to the radiopharmaceutical.  
Furthermore, dosimetric data should be collected during therapeutic cycles because many 
factors can influence the results. 
The adsorbed doses, especially with regards to the tumour, are affected by wide intra-
patient variation between treatment cycles.  The adsorbed dose to the tumour is higher 
during the first two cycles with a gradually reduced uptake in the following treatments, 
probably due to saturation or down-regulation of peptide receptors. Tumour adsorbed dose 
should exceed 100 Gy to obtain a therapeutic  effect, with better results for higher doses 
(about 230 Gy).  
Nephrotoxicity is the dose-limiting factor, due to renal reabsorption and retention of 
radiolabeled peptides that results in high kidney radiation doses.   
The renal adsorbed dose is influenced by the radionuclide emission: using a microdosimetry 
model, Konijnenberg et al. (2004) found that 111In- and 177Lu-labelled somatostatin analogues 
www.intechopen.com
 
Internal Radiation Dosimetry: Models and Applications 
 
43 
are likely to have higher renal toxicity thresholds than 90Y, whose emitted electrons have a 
path length of 12 mm.  
Renal doses can be reduced by co-administration of basic amino acids, bovine gelatine-
containing solution Gelofusine or albumin fragments, which interfere with the radiopeptide 
reabsorption pathway to achieve kidney protection. Amino acids, in particular, are already 
commonly used in the clinical setting during PRRT, being able to reduce the kidney 
adsorbed dose consistently (25-65% with respect to baseline data). The dose fraction 
markedly influences the total tolerated dose. 
The dose to kidneys should not exceed a limit value of 28 Gy, established for external beam 
radiotherapy, which results in a 50% probability of developing severe late renal failure. 
Nevertheless, for the difference between the two radiation therapy modalities, this 
recommendation has been questioned and the biological effective dose (BED) is considered 
a more accurate quantity, with a good correlation with the loss of kidney function.  
BED for a given organ or tissue was defined in Equation 18. We recall that BED is a function 
of the doses imparted in each PRRT cycle, and depends upon the effective half-time of the 
radiopeptide in the organ and upon its intrinsic radiosensitivity. 
Data in literature show that patients with risk factors, such as hypertension and diabetes, 
should not receive a BED higher than 28 Gy, while patients with no risk factors might have a 
renal BED threshold of 40 Gy (Bodei, 2008).  
The risk of bone marrow toxicity increases with increasing therapeutic dose. Studies aimed 
to increase the therapeutic dose (more cycles, higher dose per cycle, improvement in specific 
activity of the compound) to the tumour in a renoprotective (and bone marrow-protective) 
regimen are needed to further improve PRRT with somatostatin analogues in the future. 
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